Myriad Genetics (MYGN) Other Accumulated Expenses (2014 - 2020)

Myriad Genetics (MYGN) has 7 years of Other Accumulated Expenses data on file, last reported at $22.4 million in Q2 2020.

• Other Accumulated Expenses for Q2 2020 came in at $22.4 million, up 146.15% year-over-year; the trailing twelve-month figure through Jun 2020 was $22.4 million (up 146.15% YoY), and the FY2020 annual result was $22.4 million, up 146.15% from the prior year.
• Other Accumulated Expenses grew to $22.4 million in Q2 2020 per MYGN's latest filing, from $4.3 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $22.4 million in Q2 2020 and troughed at $4.3 million in Q1 2020.
• A 5-year average of $13.3 million and a median of $13.8 million in 2016 frame the typical range for Other Accumulated Expenses.
• On a YoY basis, Other Accumulated Expenses climbed as much as 146.15% in 2020 and fell as far as 80.09% in 2020.
• A 5-year view of Other Accumulated Expenses shows it stood at $13.7 million in 2016, then climbed by 13.87% to $15.6 million in 2017, then grew by 13.46% to $17.7 million in 2018, then sank by 53.67% to $8.2 million in 2019, then soared by 173.17% to $22.4 million in 2020.
• Business Quant data shows MYGN's Other Accumulated Expenses at $22.4 million in Q2 2020, $4.3 million in Q1 2020, and $8.2 million in Q4 2019.